187 results on '"Hige S"'
Search Results
2. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
3. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region
4. Successful allogeneic bone marrow transplantation from an HBV-positive donor into an HBV-positive recipient using lamivudine
5. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation
6. Helicobacter pylori infection in two areas in Japan with different risks for gastric cancer
7. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
8. PRECORE AND CORE PROMOTER MUTATIONS IN PATIENTS WITH HEPATITIS B VIRUS GENOTYPE B OR C IN JAPAN
9. PREVALENCE OF HEPATITIS B VIRUS GENOTYPE IN JAPAN AND ITS CLINICAL SIGNIFICANCE
10. Distribution and changes of FIB-4 index in normal health checkup examinees
11. Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis
12. Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
13. Combined hepatocellular carcinoma and cholangiocarcinoma growing into the common bile duct
14. Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
15. The Real World Experience of Daclatasvir and Asunaprevir Combination Therapy for More Elderly Patients thanthe Clinical Trial Subjects with Genotype 1b Chronic Hepatitis C
16. SAT-099 - Distribution and changes of FIB-4 index in normal health checkup examinees
17. FRI-384 - Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
18. FRI-330 - Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis
19. Change of anti-HCV antibody titer during interferon therapy. Investigation of NS3, NS4 and core region antibody
20. P0997 : WFA+-M2BP is a predictive factor for fibrosis progression in NAFLD
21. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia.
22. P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPY
23. SAT-261 - The Real World Experience of Daclatasvir and Asunaprevir Combination Therapy for More Elderly Patients thanthe Clinical Trial Subjects with Genotype 1b Chronic Hepatitis C
24. FRI-122 - Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
25. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
26. 835 RBV BLOOD CONCENTRATION AT FIRST WEEK OF PEG-IFN/RBV/TVR COMBINATION THERAPY IS A GOOD PREDICTIVE MARKER OF RENAL DYSFUNCTION AND ANEMIA
27. 1035 HEAT SHOCK FACTOR 1 ACCELERATES HEPATOCELLULAR CARCINOMA DEVELOPMENT BY ACTIVATING NUCLEAR FACTOR κB/MITOGEN-ACTIVATED PROTEIN KINASE
28. 825 ANALYSIS OF THE OPTIMAL TVR DOSE PER WEIGHT JUDGING FROM ANEMIA DURING PEG-IFN/RBV/TVR COMBINATION THERAPY
29. Differential flotation centrifugation study of hepatitis C virus and response to interferon therapy
30. The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B
31. Relationship Between Serum 2-5AS Activity and the Reduction of HCV-RNA During Interferon Therapy
32. 726 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS IN THE HLA-DP LOCUS ASSOCIATED WITH CHRONIC HEPATITIS B
33. 704 MUTAGENIC AND BIOCHEMICAL EFFECTS OF RIBAVIRIN PRECEDED TO INTERFERON TREATMENT FOR PATIENTS WITH CHRONIC HEPATITIS C
34. 367 8-OHDG IS A RISK FACTOR FOR DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
35. [523] QUANTIFICATION OF HBV MUTANTS AGAINST LAMIVUDINE BY THE PNA-MGB METHOD DURING THE COURSE OF BREAKTHROUGH HEPATITIS
36. Feasibility Study of Real-Time Tumor-Tracking Radiotherapy (RTRT) for Highly-Selected Patients with Hepatocellular Carcinoma (HCC) Untreatable with Other Modalities
37. Massive Invasion of Hepatocellular Carcinoma to the Duodenum
38. Efficacy of triple therapy with rabeprazole forHelicobacter pyloriinfection and CYP2C19 genetic polymorphism
39. Differential flotation centrifugation study of hepatitis C virus and response to interferon therapy
40. P-268 Interferon treatment of chronic hepatitis B and the mutation of pre-core region of hepatitis B virus
41. Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection.
42. [Comprehensive strategy for extermination of hepatocellular carcinoma--prevention, diagnosis and treatment]
43. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations
44. P-264 Evaluation of long term (24 weeks) interferon therapy for type B chronic hepatitis
45. Real-world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B.
46. Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
47. Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan.
48. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
49. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
50. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.